Acifer

Quick links to important sections

Acifer

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acifer

What is Acifer? Definition and General Purpose

Acifer is a pharmaceutical product containing the active ingredient Mefenamic Acid, which is classified broadly as a Nonsteroidal Anti-inflammatory Drug (NSAID). The drug is a synthetic organic compound and is designed to provide relief from pain, inflammation, and fever.


Quick Facts

Property Description
Active Ingredient Mefenamic Acid
Form Oral Capsule or Tablet
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
Origin Synthetic Organic Compound
General Use Relief of pain, inflammation, and fever

What is Acifer and What is its Composition?

Acifer is a medicine containing the single active substance Mefenamic Acid, typically prepared as a monotherapy product. It is primarily administered orally and is available in solid forms like capsules or tablets. The composition involves Mefenamic Acid combined with standard pharmaceutical excipients necessary for stability and delivery. This single-agent NSAID status distinguishes it from multi-symptom relievers that feature multiple active ingredients.


What Type of Medicine is Mefenamic Acid?

Mefenamic Acid is categorized as an Anthranilic Acid Derivative (fenamate), a specific chemical subclass within the larger NSAID group. This identification is based on its chemical structure and synthetic origin. Mefenamic Acid works by inhibiting the enzyme cyclooxygenase, a mechanism that helps reduce swelling and pain. Its nature as a synthetic compound contrasts with natural remedies, indicating its precise chemical design, recognized for its rapid onset of action compared to some other NSAID subclasses.


What is the General Use of This NSAID?

The general therapeutic purpose of Mefenamic Acid is to provide relief from mild to moderate pain and to mitigate the physical signs of inflammation and elevated body temperature. It is utilized in managing pain and inflammation, serving as an analgesic. Its core actions—analgesic, anti-inflammatory, and antipyretic—make it generally suitable for managing acute discomfort, for instance, in the context of muscular aches or temporary physical discomfort.

What side effects are possible with Acifer?

Adverse reaction scope

Serious Adverse Reactions: Acifer contains two active components, leading to potential risks associated with both:

  • Liver Damage: The acetaminophen component carries a significant risk of severe, potentially fatal liver damage (hepatotoxicity), particularly when the maximum daily dose is exceeded, when used with other acetaminophen-containing products, or with concurrent consumption of three or more alcoholic drinks daily.
  • Cardiovascular Risks: The non-steroidal anti-inflammatory drug (NSAID) component is associated with an increased risk of serious cardiovascular thrombotic events, including heart attack and stroke, which can be fatal. This risk may be higher with prolonged use or in individuals with pre-existing heart disease.
  • Gastrointestinal Risks: The NSAID component can cause severe gastrointestinal bleeding, ulceration, and perforation of the stomach or intestines, which may also be fatal. The risk is elevated in the elderly and those with a history of stomach problems or those using blood thinning medications.
  • Hypersensitivity: Severe, life-threatening allergic reactions, including anaphylaxis and severe skin reactions (e.g., Stevens-Johnson syndrome), are known risks of both components.

Population-Specific Safety Considerations

  • Geriatric Patients (Age 60+): These individuals are at a higher risk of serious gastrointestinal side effects from the NSAID component.
  • Pregnancy: Use during the last trimester is generally contraindicated due to the risk of harm to the developing fetus from the NSAID component. A healthcare provider should be consulted before use during pregnancy or breastfeeding.

Safety-Related Restrictions and Limitations

Acifer is contraindicated in patients with a known allergy to acetaminophen, aspirin, or other NSAIDs, and should not be used immediately before or after coronary artery bypass graft (CABG) surgery. It is also restricted for use in individuals with active liver disease or severe cardiovascular conditions. The maximum daily dose must not be exceeded.

Other Documented Adverse Reactions

Commonly reported adverse reactions involving various system-organ classes include gastrointestinal symptoms (nausea, vomiting, abdominal pain), dizziness, and headache.

Overdose and Emergency Response

The official regulatory profile for Acifer (Mefenamic Acid) overdose primarily documents severe manifestations impacting the Central Nervous System (CNS) and Gastrointestinal (GI) tract.

Feature Official Regulatory Statements
Documented Overdose Manifestations CNS effects, including convulsions/seizures, drowsiness, confusion, and coma, are prominently associated with Mefenamic Acid overdose. Gastrointestinal symptoms include severe stomach pain, nausea, and vomiting (potentially resembling coffee grounds or black, tarry stools). Tinnitus is also a documented sign.
Serious Outcomes & Risks Overdose can lead to severe or life-threatening outcomes such as acute renal failure, coma, and fatal gastrointestinal events (bleeding and perforation). The elderly are noted to be a population with heightened risk for these fatal GI complications.
Emergency Action & Management Seek immediate medical attention for any suspected overdose. Treatment is symptomatic and supportive as no specific antidote is known. Management procedures may include monitoring vital functions, controlling convulsions, and administration of activated charcoal, particularly when the overdose is recent.

The regulatory framework emphasizes that severe or large ingestions—including doses over 3.5 g—carry a particular risk of CNS toxicity (convulsions). This profile dictates that urgent medical help is required when overdose is suspected, especially given the lack of a specific reversal agent and the potential for rapid progression to acute renal or neurological failure. The official documentation defines the overdose structure by listing these severe, life-threatening risks and outlining the subsequent supportive care.

Therapeutic Uses of Acifer

What Acifer Treats: Main Uses and Benefits

Acifer (Mefenamic Acid) is commonly used across conditions presenting with episodic or fluctuating manifestations of discomfort, and is considered relevant for providing supportive relief for symptoms related to physical discomfort and inflammatory states. It is applicable for managing mild to moderate acute pain from various origins, including headaches, dental pain, and discomfort following minor trauma, as well as symptoms associated with inflammatory joint disorders like rheumatoid arthritis and osteoarthritis.

It is highly relevant for use in gynecological contexts: helping address symptom clusters that may become intense or disruptive during the reproductive cycle, such as the pain of primary dysmenorrhea (menstrual cramps) and symptoms linked to menorrhagia (abnormally heavy bleeding).

This application is relevant in scenarios where additional management of discomfort is required, and it generally contributes to easing the overall symptom load during phases of increased distress. It provides supportive relief that may help patients cope more steadily with difficult, recurrent episodes by addressing symptoms related to physical discomfort and inflammatory states.


Quick Fact: Symptomatic Support for Episodic Manifestations

Primary Domains Key Symptoms Eased Primary Patient Benefit
Gynecological Pain Spasmodic pain, cramping Supports coping during recurrent episodes
Musculoskeletal Pain, stiffness, localized swelling Contributes to improved day-to-day comfort
General Acute Headaches, dental pain, fever Eases the overall symptom load

Regulatory References

  1. The NIH MedlinePlus overview

Eligibility and Restrictions for Use

Acifer (ferric maltol) is a prescription oral iron supplement used to treat iron deficiency in adults. It is essential to consult with a healthcare provider to determine if this medication is appropriate for your specific health needs.


Who Can and Cannot Use Acifer

Can Use Should Not Use (Contraindicated)
Adults with confirmed iron deficiency. Patients with hypersensitivity (allergy) to ferric maltol or any inactive ingredient.
Pregnant and breastfeeding individuals should discuss use with a doctor. Patients with iron overload syndromes, such as hemochromatosis or hemosiderosis.
Patients receiving repeated blood transfusions, which can lead to iron overload.

Key Safety Considerations

  • Inflammatory Bowel Disease (IBD): Use of Acifer should be avoided in patients with an active IBD flare, as there is a risk of increased gastrointestinal inflammation.
  • Iron Overload: Your healthcare provider will monitor your iron parameters before and during treatment to prevent excessive iron storage, which can be harmful. The risk of accidental overdose is particularly serious and potentially fatal in children under 6; keep the medication out of reach.
  • Pediatric Use: The safety and effectiveness of Acifer have not been established in children under 18 years of age.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the interactions of Acifer (ferric maltol) that have been officially documented in government regulatory labeling. The co-administration of Acifer with certain other substances requires specific precautions, monitoring, or restrictions.

Contraindicated and Restricted Combinations

Specific substances are restricted due to the potential for significant adverse outcomes when combined with Acifer. Concomitant use with dimercaprol is strictly avoided.

Interaction Classification and Constraints

The most frequent category of interaction involves the impact on absorption for both Acifer and other co-administered oral medications. This is primarily managed through strict timing-based interaction rules.

Interaction Type Interacting Substance/Class Required Action
Toxicity Risk Dimercaprol Avoid use
Absorption Interference Certain Oral Medications Separate administration

Procedural Interaction Requirements

For certain oral medications, regulatory labeling requires that Acifer administration be separated by a specified time interval to prevent interference with the absorption or bioavailability of either product. Additionally, a careful monitoring of clinical response is necessary when Acifer is co-administered with any substance known to be affected by iron or with any substance where absorption may be reduced.

The regulatory profile defines constraints that focus on preventing chelation-related toxicity and optimizing the systemic exposure of Acifer and other critical co-medications.

Mechanism of Action

Acifer is classified as a carbonic anhydrase inhibitor (CAI), exerting its primary pharmacological action through non-competitive inhibition of the carbonic anhydrase enzyme, which is widely distributed across various tissues, including the proximal renal tubules and the ciliary body epithelium of the eye.

In the renal proximal tubule cells, Acifer's inhibition of intracellular and brush-border carbonic anhydrase prevents the hydration of carbon dioxide and the subsequent dissociation of carbonic acid. This action leads to a decrease in the availability of intracellular hydrogen ions and a reduction in the reabsorption of filtered bicarbonate (HCO3^-). Consequently, the concentration of HCO3^- in the tubular lumen increases, leading to HCO3^- excretion and the resulting urinary alkalization. The concurrent osmotic effect and retention of water in the tubule produce a systemic diuresis and a decrease in extracellular fluid volume.

In the ciliary body epithelium, the inhibition of carbonic anhydrase reduces the production of bicarbonate ions, a critical component of aqueous humor secretion. The resulting decrease in aqueous humor formation leads to a modulation of intraocular fluid pressure.

Dosage and Administration Information

Administration and Dosing Principles

Acifer (Mefenamic Acid) is solely administered via the oral route as a capsule or tablet, which must be swallowed whole. It is taken with food, milk, or a full glass of water (8 to 12 ounces) to ensure proper administration and reduce potential gastrointestinal effects.


Standard Regimen and Frequency

The standard adult dosing regimen for acute treatment begins with a 500 mg initial dose, followed by a 250 mg maintenance dose taken every 6 hours (q6hr) as needed. Treatment for cyclical symptoms, such as primary dysmenorrhea, requires initiation promptly at the onset of bleeding or pain to be effective. The overall usage must adhere to the principle of using the lowest effective dose for the shortest duration.


Duration Constraints and Special Use

The medicine is strictly intended for short-term use. For general acute pain, the duration of treatment must not exceed 7 days. For recurrent conditions, such as menstrual pain, the usage is typically limited to 2 to 3 days per cycle. The drug is approved for patients 14 years of age and older. Special caution and possible dose adjustment are mandated for older adults and those with hepatic impairment. If a dose is missed, it is appropriate to skip it and return to the regular schedule to avoid doubling the next dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Acifer

The research on Acifer (Mefenamic Acid) focuses on how it was studied for its approved uses. This overview describes the types of research conducted, the outcomes that were measured, and what remains unknown, based on authoritative scientific and regulatory sources.


Evidence for Use in Primary Dysmenorrhea (Menstrual Cramps)

Research exploring short-term symptom changes in women with primary dysmenorrhea has commonly used Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies monitored outcomes related to physical discomfort, primarily focusing on measured changes in pain intensity using standardized assessment scales over the course of one or more menstrual cycles.

Studies reported how symptoms evolved, and the findings describe patterns observed in the studies regarding the need for additional pain-relieving medication. However, long-term outcomes are not well characterized regarding the agent's use over many years of intermittent, cyclical administration.


Evidence for Use in Acute Pain (Mild to Moderate)

Evidence comes largely from single-dose, short-observation RCTs applied in research contexts involving fluctuating or unstable symptoms, such as post-operative or dental discomfort. Researchers monitored patient-reported outcomes describing perceived discomfort and measures such as the time it takes to report an initial change in symptom intensity.

These studies report how symptoms evolved over the initial four to six hours following a single dose. The available data are limited to the very short-term management of acute discomfort and do not address research covering sustained discomfort management.


Key Research Gaps and Unanswered Questions

Research highlights that follow-up durations were limited for many core indications, particularly for use extending beyond acute or cyclical episodes. Evidence consistency varies across studies, and subgroup findings are uncertain regarding the patterns observed in patients with certain comorbidities or advanced age. Overall, long-term outcomes, especially in chronic use, are not fully established.

Key Studies & References

  1. Mefenamic Acid (Philippine FDA Monograph - broader indication list, including Menorrhagia/Joint Conditions)
  2. Efficacy of minor analgesics in primary dysmenorrhoea: a systematic review (includes Mefenamic Acid RCT data)
  3. Mefenamic Acid - LiverTox: Clinical and Research Information on Drug-Induced Liver Injury (Source for chronic/long-term use data and safety context)

Frequently Asked Questions (FAQ)

Common questions about Acifer (FAQ)

Q: How quickly can I expect to feel the effects of Acifer?

A: Studies conducted for acute pain monitored the time it takes for people to notice an initial change in their symptom intensity. Official product information for the Mefenamic Acid component shows a short elimination half-life of roughly two to four hours, which is consistent with expectations for symptom-relief onset. The Ferric Maltol component generally reaches its highest concentration in the blood within one to three hours after administration.

Q: Can Acifer be taken with common pain relievers like ibuprofen or aspirin?

A: Regulatory warnings indicate its use in combination with aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) such as ibuprofen is generally avoided, due to increased risk of side effects, including gastrointestinal bleeding. The iron supplement component also requires careful consideration and possible monitoring when co-administered with other oral medications.

Q: Are there any common foods or drinks I should avoid while using Acifer?

A: Official administration instructions state that the medicine is typically administered with food or milk to help reduce the potential for stomach upset. For the iron component, absorption may be lowered by certain foods, including dairy products and items containing phytic acid. Consumption of alcohol alongside the NSAID component is warned against, as it can increase the risk of stomach bleeding.

Q: Can individuals with a history of kidney issues generally use Acifer?

A: Regulatory documents indicate that the NSAID component of Acifer is generally contraindicated in patients with severe kidney disease or significantly impaired renal function. The medication carries a risk of renal (kidney) toxicity. Special caution and possible dose adjustments are also noted for older adults due to the potential for age-related changes in kidney function.

Q: Can people who are lactose intolerant or have allergies to certain dyes use Acifer?

A: The medicine is strictly contraindicated for anyone with a known hypersensitivity or allergy to the active ingredients or any of the inactive ingredients, which may include excipients like dyes or lactose. Patients may wish to review the full list of inactive ingredients on the product labeling for potential allergens.

Q: Why do some people stop using Acifer after a short time?

A: Regulatory guidance indicates that the NSAID component of Acifer is strictly intended for short-term use, with treatment for acute pain not intended to exceed seven days due to the risk of serious side effects. Furthermore, the medication should be discontinued if a patient experiences signs of severe adverse effects or persistent common effects like severe diarrhea.

Q: Can I crush or split Acifer tablets?

A: Official administration instructions specify that Acifer capsules or tablets are intended to be swallowed whole, rather than being crushed or split. This requirement is in place to ensure that the medication is released and absorbed properly into the body.

Q: Do official documents mention a specific time of day Acifer should be used?

A: Official dosing guidelines specify the recommended frequency of use, such as every six hours, to maintain consistent levels of the drug in the body. However, regulatory documents do not mandate a specific time of day (morning or night) for the initial dose; the timing is generally dependent on the nature of the patient’s symptoms.

Q: Does Acifer cause drowsiness or affect driving?

A: Official labeling for the NSAID component of Acifer lists dizziness and somnolence (drowsiness) as possible side effects. Due to these potential effects, patients should be aware of them when engaging in activities requiring mental alertness, such as driving or operating machinery.

Q: How long does Acifer stay in your system after stopping use?

A: The time a medicine stays in the body is generally defined by its elimination half-life. For Mefenamic Acid, the half-life is approximately two to four hours. The maltol component of Ferric Maltol has an elimination half-life of about 0.7 hours.

Q: Does Acifer interact with herbal supplements like St. John's Wort?

A: Regulatory sources address the importance of disclosing all products being taken, including herbal products and nutritional supplements. Interactions are possible with both NSAIDs and iron supplements, and this information may necessitate closer monitoring or dose considerations.

Q: What if I'm taking vitamins; do they interfere with Acifer?

A: Interactions are possible, particularly with the iron component. The absorption of Ferric Maltol can be affected by minerals like calcium and magnesium, which are common in multivitamins. Furthermore, separation of administration times may be necessary to minimize interference with the absorption of other co-administered substances.

Q: Is Acifer a habit-forming or controlled substance?

A: Official scheduling from government drug enforcement agencies indicates that Acifer, in both the Mefenamic Acid and Ferric Maltol forms, is classified as a prescription-only medicine (Rx). It is not currently designated as a DEA-scheduled or controlled substance.

Q: What should I do if I experience a mild side effect, according to patient resources?

A: Patient counseling information provided by regulatory agencies directs users to notify their healthcare provider if they experience signs of serious side effects. For common, mild side effects, the general patient resource advice is to communicate with a healthcare provider regarding them, especially if they become severe or persist.

Q: Are there genetic factors that influence how Acifer works for a person?

A: Regulatory information on the metabolism of the Mefenamic Acid component notes that it is processed by the enzyme CYP2C9. Genetic variations in this enzyme can lead to differences in how the drug is metabolized, potentially resulting in altered patient exposure to the medicine.

Q: Is there a generic version of Acifer available?

A: According to the FDA’s resource of approved drug products, the active ingredient Mefenamic Acid is available in generic capsule form. However, the specialized formulation of Ferric Maltol may currently only be available under its proprietary brand name.

Q: What should I know about stopping Acifer use?

A: Mefenamic Acid is intended for short-term use and should be discontinued once the condition is resolved or if the duration constraint is reached. Regulatory documents specify that the medication should be discontinued immediately if the patient experiences signs of a serious adverse reaction, such as a severe skin reaction or gastrointestinal bleeding.

Q: Why is Acifer classified as a prescription-only medicine?

A: Acifer is designated as a prescription-only medicine (POM) because its active ingredients carry known risks of serious adverse effects. These risks include severe cardiovascular, gastrointestinal, and hepatic (liver) complications, which necessitate professional oversight and monitoring.

How should Acifer be stored and disposed of?

How to Store and Dispose of Acifer (Mefenamic Acid)

Official regulatory guidelines define strict conditions for the storage and disposal of Acifer to maintain product stability and ensure safety.


Storage Conditions

  • Temperature: Store at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). Brief temperature excursions are permitted only within the range of 15 C to 30 C.
  • Protection: The product must be protected from moisture and kept in its original container with the lid tightly closed.
  • Child Safety: Acifer must be kept out of the sight and reach of children at all times.

Disposal Requirements

Expired or unused medication must be handled according to specific regulatory rules. Disposal should occur via an authorized medicine take-back program. If a program is unavailable, consult local waste disposal authorities, as the product must be discarded in accordance with local regulations and must not be poured down a drain or flushed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Acifer found in:

A-Z Index: